LATEST: Pfizer says COVID-19 vaccine more than 90% effective in kids.
Police officers in Chicago who refuse to disclose their vaccination status face suspension or termination as they stand off against the city’s vaccine mandate.Kid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Advisers to the FDA will publicly debate the evidence next week. If the agency ultimately authorizes the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them. The Biden administration has purchased enough kid-size doses — in special orange-capped vials to distinguish them from adult vaccine — for the nation’s roughly 28 million 5- to 11-year-olds. If the vaccine is cleared, millions of doses will be promptly shipped around the country, along with kid-size needles.
In addition, young children given the low-dose shots developed coronavirus-fighting antibody levels just as strong as teens and young adults who got regular-strength vaccinations. Pfizer’s study of younger kids found the low-dose shots proved safe, with similar or fewer temporary side effects such as sore arms, fever or achiness that teens experience.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Pfizer says COVID-19 vaccine more than 90% effective in kidsKid-size doses of Pfizer’s COVID-19 vaccine appear safe and nearly 91% effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group. The shots could begin in early November — with the first children in line fully protected by Christmas — if regulators give the go-ahead. Details of Pfizer's study were posted online.
続きを読む »
Pfizer, BioNTech report high efficacy of COVID-19 booster shot in studyPfizer Inc and German partner BioNTech SE on Thursday said data from a Phase III trial demonstrated high efficacy of a booster dose of their COVID-19 vaccine against the virus, including the Delta variant.
続きを読む »
Pfizer Says Its Booster Shot Shows 95.6% Efficacy Against Covid-19I am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
続きを読む »
Pfizer-BioNTech Covid-19 Booster Shot Was 95.6% Effective in Large Trial, Companies SayThe study was carried out while the highly contagious Delta variant was prevalent, the companies said, suggesting the booster helps protect against the contagious strain.
続きを読む »
New Zealand sets 90% vaccine target to end Covid lockdown – latest updatesNew Zealand sets 90 percent vaccination target to end lockdowns. Other Covid19 updates: 🇲🇽 Mexico's death toll rises to 285,669 💉 CDC expands booster rollout, OKs mixing shots 🇧🇷 Brazil sees 16,853 cases For more:
続きを読む »
India celebrates 1 billion COVID-19 vaccine doses with song and danceIndia celebrated the milestone of administering one billion COVID-19 vaccine doses on Thursday, with the government promoting the achievement in song and video even as a recent drop in inoculations worries healthcare providers.
続きを読む »